LHP588 is a novel oral therapeutic developed by Lighthouse Pharmaceuticals targeting Porphyromonas gingivalis (P. gingivalis), a bacterium linked to Alzheimer's disease pathogenesis through the periodontal disease mechanism. This Phase 2 trial investigates whether targeting this pathogen can halt or slow AD progression in patients with confirmed P. gingivalis infection.
The trial represents a paradigm shift in Alzheimer's disease therapeutic development by targeting a potential upstream trigger rather than downstream amyloid or tau pathology. By addressing the bacterial infection that may drive neuroinflammation and protein aggregation, LHP588 could provide disease-modifying effects through a novel mechanism distinct from all currently approved AD treatments[@lighthouse].
| Parameter |
Value |
| NCT Number |
NCT06847321 |
| Status |
RECRUITING |
| Phase |
Phase 2 |
| Sponsor |
Lighthouse Pharmaceuticals, Inc. |
| Intervention |
LHP588 (oral) |
| Doses |
25 mg, 50 mg, placebo |
| Randomization |
1:1:1 |
| Duration |
48 weeks (oral, once daily) |
| Enrollment |
~150 participants |
| Start Date |
2024 |
| Completion |
2026 |
The link between P. gingivalis and Alzheimer's disease represents one of the most compelling examples of the infectious etiology hypothesis of neurodegeneration. Extensive research has established multiple pathways through which this oral pathogen may contribute to AD pathogenesis[@dominy2019]:
P. gingivalis is the primary pathogen in chronic periodontitis (gum disease) and possesses several virulence factors that may impact brain health:
-
Gingipains
The gingipains (RgpA, RgpB, Kgp) are a family of cysteine proteases that:
- Degrade host proteins for bacterial nutrition
- Activate pro-inflammatory responses
- Can degrade amyloid precursor protein (APP)
- May cleave tau protein, potentially promoting neurofibrillary tangle formation
- Disrupt tight junctions in the blood-brain barrier
-
Lipopolysaccharide (LPS)
- P. gingivalis LPS triggers Toll-like receptor 4 (TLR4) signaling
- Promotes neuroinflammation through microglial activation
- Can access the brain via circulatory system or olfactory pathway
-
Fimbriae
- Bacterial surface structures that enable tissue invasion
- Facilitate bacterial spread beyond the oral cavity
Chronic periodontal infection creates a state of elevated systemic inflammation that may affect brain health:
- Elevated Cytokines: Increased IL-1β, IL-6, TNF-α levels
- C-Reactive Protein: Elevated inflammatory markers
- Cross-Reactive Antibodies: Immune response may cross-react with brain antigens
Multiple mechanisms may allow P. gingivalis or its components to access the central nervous system:
- Direct Invasion: Bacterial components may cross the blood-brain barrier (BBB)
- Olfactory Pathway: Bacteria may travel via the olfactory nerve to the brain
- Trojan Horse: Infected immune cells may carry bacteria across the BBB
- Vascular Route: Compromromised cerebrovascular integrity in AD may facilitate entry
¶ Amyloid and Tau Interactions
Gingipains may interact with the hallmark proteins of Alzheimer's disease:
- Amyloid Processing: Gingipains may promote amyloid-β production
- Amyloid Degradation: May also degrade amyloid plaques, complicating interpretation
- Tau Cleavage: Gingipains can cleave tau protein, potentially promoting tangle formation
- Microglial Activation: Chronic bacterial presence may prime microglia toward a pro-inflammatory phenotype
LHP588 is designed to target P. gingivalis through oral administration:
- Bacterial Load Reduction: Oral administration targets bacteria in the oral cavity and gastrointestinal tract
- Gingipain Inhibition: May reduce proteolytic activity that drives inflammation
- Systemic Effects: By reducing chronic infection burden, may decrease systemic and CNS inflammation
- Microbiome Modulation: May shift oral microbiome toward healthier state
| Feature |
LHP588 |
Anti-Amyloid Antibodies |
| Target |
P. gingivalis |
Amyloid-β |
| Delivery |
Oral |
IV infusion |
| Mechanism |
Upstream trigger |
Downstream pathology |
| Patient Selection |
P. gingivalis positive |
Biomarker positive |
| Side Effect Profile |
Oral drug profile |
ARIA |
This is a Phase 2, randomized, double-blind, placebo-controlled trial with multiple arms:
| Arm |
Dose |
Participants |
| Low Dose |
25 mg LHP588 daily |
~50 |
| High Dose |
50 mg LHP588 daily |
~50 |
| Placebo |
Matching placebo |
~50 |
- Age: 55-80 years
- Diagnosis: Alzheimer's disease (probable AD per NIA-AA criteria)
- Cognitive Status: MMSE score 12-24 (mild-to-moderate dementia)
- Infection Status: P. gingivalis infection confirmed via saliva PCR
- Biomarker: Elevated plasma pTau217 above pre-specified cutoff
- Caregiver: Identified caregiver to assist with compliance and assessments
- Recent Cancer Therapy: Any cancer therapy within 2 years
- Cardiovascular: Unstable cardiovascular disease
- Hypertension: Uncontrolled hypertension (>180/100 mmHg)
- Anti-Amyloid Therapy: Current or recent anti-amyloid treatments
- No lecanemab, donanemab, or Aduhelm within 6 months
- Antibiotics: Recent antibiotic use that may affect oral microbiome
- Active Periodontal Disease: Active periodontal treatment
| Phase |
Duration |
| Screening |
12 weeks |
| Treatment |
48 weeks |
| Follow-up |
4 weeks |
| Total |
~64 weeks (~16 months) |
| Visit |
Timepoint |
Assessments |
| Screening |
-12 to 0 weeks |
Medical history, cognitive testing, microbiome sampling |
| Baseline |
Week 0 |
Randomization, baseline measures |
| Treatment |
Weeks 4, 12, 24, 40 |
Safety, efficacy assessments |
| End of Treatment |
Week 48 |
Full cognitive and functional assessment |
| Follow-up |
Week 52 |
Safety and survival follow-up |
- Change from baseline in ADAS-Cog11 at Week 40-48
- Alzheimer's Disease Assessment Scale - Cognitive subscale (11-item)
- Measures memory, language, praxis, and orientation
- The primary cognitive endpoint in AD clinical trials
-
Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB)
- Global measure of dementia severity
- Assesses cognition and function across 6 domains
-
ADCS-ADL (Alzheimer's Disease Cooperative Study - Activities of Daily Living)
- Functional assessment measuring daily living abilities
- Sensitive to changes in mild-to-moderate AD
-
Plasma Biomarkers
- pTau217 (phosphorylated tau at threonine 217)
- Total tau
- Neurofilament light chain (NfL)
-
Oral Microbiome Markers
- P. gingivalis load in saliva
- Gingipain activity levels
- MRI Brain Volume: Hippocampal and whole brain atrophy rates
- CSF Biomarkers (in subset): Amyloid and tau levels
- Neuropsychiatric Inventory (NPI): Behavioral symptoms
This trial tests the hypothesis that targeting P. gingivalis infection may provide disease-modifying effects in Alzheimer's disease through multiple mechanisms[@periodontal2022]:
| Approach |
Target |
Stage |
| Anti-Amyloid |
Amyloid-β plaques |
Approved (lecanemab, donanemab) |
| Anti-Tau |
Tau tangles |
Investigational |
| Anti-Inflammation |
Cytokines |
Investigational |
| LHP588 |
P. gingivalis infection |
Phase 2 |
By eliminating a chronic infectious trigger:
- May slow or halt disease progression (not just symptomatic relief)
- Addresses potential root cause rather than downstream effects
- May provide benefits regardless of amyloid/tau status
The trial uses dual biomarker selection:
- Pathogen-Specific: Confirmed P. gingivalis infection
- Neurodegeneration-Specific: Elevated pTau217 indicating active AD pathology
This precision medicine approach may enrich for patients most likely to benefit from the intervention.
Unlike lecanemab, donanemab, and Aduhelm:
- No risk of amyloid-related imaging abnormalities (ARIA)
- Oral delivery rather than intravenous infusion
- Different side effect profile
- May be accessible to broader patient population
This trial represents a significant advancement in AD therapeutic development for several reasons:
- Infectious Etiology Hypothesis: Tests the controversial but evidence-supported hypothesis that chronic infections contribute to neurodegeneration
- Targeting Upstream Triggers: Rather than clearing established pathology, targets potential initiating factors
- Prevention Potential: Could potentially prevent disease progression if initiated early
¶ Treatment Landscape
| Drug |
Mechanism |
Status |
Limitations |
| Donepezil |
Cholinesterase inhibition |
Approved |
Symptomatic only |
| Memantine |
NMDA antagonism |
Approved |
Modest effect |
| Lecanemab |
Anti-Aβ |
Approved |
IV infusion, ARIA |
| Donanemab |
Anti-Aβ |
Approved |
IV infusion, ARIA |
| LHP588 |
Anti-bacterial |
Phase 2 |
Investigational |
If successful, LHP588 could offer:
- Oral Administration: More convenient than antibody infusions
- Broader Eligibility: No amyloid PET requirement
- Combination Potential: Could potentially be combined with other AD treatments
- Earlier Intervention: May benefit patients before extensive pathology develops
The field has seen previous attempts to target infections in AD:
- Cortexyme COR388: Earlier gingipain inhibitor that showed promise in Phase 1/2 but program was discontinued
- Antibiotic Trials: Broad-spectrum antibiotics showed mixed results
- Valacyclovir: Herpes simplex virus targeting showed some promise
LHP588 builds on lessons from these programs with improved drug design and better patient selection.
Based on Phase 1 data and the drug's mechanism:
- Gastrointestinal: Mild GI symptoms possible
- Oral: Minimal - targets oral bacteria locally
- No ARIA Risk: Unlike anti-amyloid antibodies
- Regular safety labs
- Adverse event monitoring
- Vital signs and physical exams
- Oral examination for periodontal status
¶ Competitive Landscape
| Company |
Drug |
Mechanism |
Stage |
| Lighthouse |
LHP588 |
Gingipain inhibitor |
Phase 2 |
| Cortexyme |
Discontinued |
Gingipain inhibitor |
Former Phase 2 |
| Viacyte |
VX-880 |
Stem cell |
Phase 1/2 |
| AriBio |
AR1001 |
Multiple |
Phase 2 |
The trial is being conducted at major memory clinics and research centers including:
- Multiple sites in the United States
- European sites
- Potential sites in other regions
- NCT06847321 - Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
- Dominy et al., Porphyromonas gingivalis in the brain in Alzheimer's disease (2019)
- Cortexyme COR388 (Atuzabtagene) - AlzForum
- Singhrao et al., Periodontal disease and Alzheimer's disease: a bidirectional relationship (2022)
- Guo et al., Gingipains as therapeutic targets in Alzheimer's disease (2020)
- Kantarcioglu et al., The role of Porphyromonas gingivalis in Alzheimer's disease pathogenesis (2022)
- Sato et al., P. gingivalis infection and cognitive decline in Alzheimer's disease (2022)
- Islek et al., Oral microbiome and neurodegeneration (2023)
- Chen et al., Antibacterial approaches to Alzheimer's disease treatment (2024)
- Lighthouse Pharmaceuticals - LHP588 Program
- Dominy et al., Porphyromonas gingivalis in Alzheimer disease: Evidence for disease causation (2019)
- Singhrao et al., Porphyromonas gingivalis Periodontal Infection and Alzheimer's Disease (2015)
- Chen et al., Association between chronic periodontitis and Alzheimer's disease: A meta-analysis (2017)
- Ilievski et al., Chronic oral application of P. gingivalis induces cerebrovascular pathology (2023)
- Poole et al., Periodontitis-associated bacteria in the brain reflects oral infection (2019)
- Sparks Stein et al., Alzheimer disease and the microbiome: Causation or correlation? (2023)
- Liu et al., LPS induces neuroinflammation and impairs lysosomal function in astrocytes (2022)
- Arai et al., Periodontitis and the gut microbiome in subjects with mild cognitive impairment (2023)
- Grenier et al., Role of tetracycline derivatives in neurodegenerative diseases (2021)
- Kamer et al., Periodontal disease associates with higher brain amyloid load (2015)
- Batista et al., Periodontitis as a Risk Factor for Alzheimer Disease: Systematic Review (2022)
- Olsen et al., P. gingivalis in Alzheimer's disease brain: A systematic review (2021)
- Dioguardi et al., Correspondence Between Periodontitis and Alzheimer's Disease (2021)
- Carter et al., Gingipain inhibitors as therapeutic agents in Alzheimer's disease (2020)